J&J: COVID-19 Vaccine Trial Pause Does Not Affect Manufacturing Plans

Johnson & Johnson’s decision to temporarily pause its COVID-19 vaccine phase 3 clinical trial because of an “unexplained illness” in a trial participant does not affect the company’s manufacturing processes and plans, a J&J official told investors on Tuesday (Oct. 13). Once the trial hold is lifted, the company will move forward with completing enrollment in its phase 3 trial. As the company awaits more information on the adverse event, it continues to plan for further testing, including a future...